Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Leases: 2016-2025

Historic Current Leases for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Sep 2025 value amounting to $3.1 million.

  • Enanta Pharmaceuticals' Current Leases rose 106.43% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 106.43%. This contributed to the annual value of $3.1 million for FY2025, which is 106.43% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Current Leases of $3.1 million as of FY2025, which was up 106.43% from $1.5 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Current Leases registered a high of $5.3 million during FY2023, and its lowest value of $1.5 million during FY2024.
  • For the 3-year period, Enanta Pharmaceuticals' Current Leases averaged around $3.3 million, with its median value being $3.1 million (2025).
  • Its Current Leases has fluctuated over the past 5 years, first crashed by 71.11% in 2024, then skyrocketed by 106.43% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Current Leases (Yearly) stood at $4.2 million in 2021, then slumped by 31.22% to $2.9 million in 2022, then surged by 82.46% to $5.3 million in 2023, then plummeted by 71.11% to $1.5 million in 2024, then spiked by 106.43% to $3.1 million in 2025.